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Abstract
Background: The increasingly complex programs of contemporary cancer therapy emphasize the need for
biological indicators of both therapeutic response and adverse effects. One example is combined-modality
treatment aimed at improving long-term outcome in patients with locally advanced rectal cancer, which commonly
comes at the price of extended limits of patient tolerance.
Methods: In a prospective study with intensified neoadjuvant treatment of rectal cancer patients, using an
antibody array, the profiling of approximately 500 proteins was performed in serial serum samples collected at
different stages of the treatment course.
Results: The small number of proteins whose levels significantly changed after induction neoadjuvant
chemotherapy (NACT) expanded substantially following the sequential chemoradiotherapy (CRT) and persisted
four weeks later at treatment evaluation before pelvic surgery. Serum levels of proteins selected for validation
of the experimental design, lipocalin-2 and matrix metalloproteinase-9, declined after NACT and gradually
reverted to baseline values during the remaining neoadjuvant course. Of note, the greater the decline in
post-NACT and post-CRT matrix metalloproteinase-9 levels, the more favorable progression-free survival. No
correlation was found, however, with diarrhea scores, the clinical correlate of adverse therapeutic effects.
Conclusions: Even though the findings were indicative of only tumor and not normal tissue effects, multiplex
immunoassay analysis of circulating proteins in patients undergoing combined-modality therapy may in
principle dissect the contribution of the individual modalities to overall systemic responses in patient
outcome and tolerance.
Trial registration: ClinicalTrials.gov NCT00278694; registration date: January 16, 2006, retrospective to
enrollment of the first 10 patients of the current report.
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Background
Colorectal cancer is characterized by heterogeneity at
the molecular level and a complex tumor microenviron-
ment [1]. Not surprisingly, patients may display very dif-
ferent responses to therapy, and treatment adapted to
molecular markers has not always led to the expected
outcome [2]. Moreover, the functional network of im-
mune factors and the location and density of immune
cells within the tumor microenvironment also contribute
to the final clinical outcome [3, 4].
In treatment of locally advanced rectal cancer (LARC)
with standard chemoradiotherapy (CRT) followed by
surgery, local recurrence rates are low but metastatic
disease remains a dominant cause of failure. The attempt
of improving survival outcome by intensifying multi-
modal treatment protocols often extends towards the
limits of normal tissue tolerance [5]. Prediction markers
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of treatment efficacy and toxicity might therefore assist
in achieving more individualized treatment in LARC.
Multiplex analysis of protein patterns in tumors and
systemically is one way of questing potential biomarkers
[6]. Conceptually, detection of circulating proteins repre-
sents a negligibly invasive procedure by which the chan-
ging microenvironment within the tumor and its
systemic manifestations, as well as the constitutional
and acquired physiology of the patient, can be moni-
tored in real-time. As such, correlation of proteins re-
leased into the circulation before, during, and after
treatment with clinical parameters could enable the
identification of biological indicators of treatment re-
sponse and adverse effects.
Here, we have employed a commercially available anti-
body array technology to monitor serum levels of ap-
proximately 500 proteins in LARC patients within the
context of a prospective study with an intensified neoad-
juvant treatment schedule [7]. In this, the patients re-
ceived induction neoadjuvant chemotherapy (NACT)
and sequential CRT [8]. Serial serum samples were col-
lected at baseline, following NACT (post-NACT), at
CRT completion (post-CRT), and at evaluation of the
neoadjuvant treatment four weeks thereafter (Fig. 1).
The collection of proteins detected by the array analysis
included immune factors, epithelial and vascular growth
factors, and proteinases among others, which were antic-
ipated to reflect proteins being released into the circula-
tion from the tumor as well as from other tissues as an
adverse response to treatment. Serum protein levels,
which were technically validated by single-parameter
analysis (enzyme-linked immunosorbent assay (ELISA)
measurements) of the tumor microenvironmental factors
lipocalin-2 (LCN2) and matrix metalloproteinase-9
(MMP9) [9, 10], were further correlated to progression-
free survival (PFS) and treatment toxicities as prospect-
ively assessed by Common Terminology Criteria for Ad-
verse Events (CTCAE) scoring. Even though the present
report showed an association between circulating MMP9
and treatment outcome but not tolerance, and it cannot
be regarded as anything more than a pilot study, such a
protein array analysis of serial serum samples may repre-
sent a rational approach for obtaining more global
insight into systemic responses to increasingly complex
programs of combined-modality radiotherapy.
Methods
Patients and treatment
The patient population within the current report, which
is based on a prospective therapy study with five years of
patient follow-up, was enrolled from October 5, 2005
through March 3, 2010. Patient eligibility criteria, evalu-
ation procedures, and review procedures of follow-up
have been detailed previously [8]. Because of the rela-
tively low number of cases in the current set of analyses
(n = 66 or lower, depending on the specific analysis;
Additional file 1: Table S1), risk-adapted stratification of
patients based on detailed tumor characteristics available
from magnetic resonance imaging was waived. As out-
lined in Fig. 1, the treatment protocol consisted of
induction NACT in terms of four weeks of oxaliplatin-
containing chemotherapy followed by CRT. Radiation
was delivered in daily 2-Gy fractions five days per week
over a 5-week period with concomitant oxaliplatin
weekly and capecitabine on days of radiation. Formal re-
cording of adverse events, using CTCAE version 3.0,
was performed throughout the neoadjuvant course. Sur-
gery was planned 6–8 weeks after completion of the
neoadjuvant treatment. In accordance with national
guidelines at the time, patients did not proceed to fur-
ther therapy.
Serum sampling
From the 66 study cases within the current report (Add-
itional file 1: Table S1), serum had been collected at base-
line (n = 66), post-NACT (n = 61), post-CRT (n = 59), and
at the time of treatment evaluation (n = 55). The collec-
tion, processing, and storage of samples followed a stan-
dardized protocol, where blood was drawn in plain serum
tubes with no additives for centrifugation to separate
serum, which was left on ice for no more than one hour
before storage at −80 °C. The antibody array analysis was
undertaken in January 2013 (i.e., after 31–87 months of
storage) and the ELISA analysis in November 2014 (i.e.,
after 53–109 months), all after only one freeze/thaw cycle
of the samples.
Fig. 1 The timing of blood sampling (red arrows) within the treatment protocol. Black arrows indicate the start of each cycle of induction
neoadjuvant chemotherapy (NACT) and of each consecutive week of the sequential chemoradiotherapy (CRT). A study-specific evaluation was
undertaken before surgery, which was accomplished when the patient had recovered from the neoadjuvant therapy (commonly 2–4 weeks
after evaluation)
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Antibody array technology and data analysis
Serum samples were analyzed with a high-density anti-
body array that was chosen for the coverage of stromal
proteins such as immune factors, epithelial and vascular
growth factors, and proteinases (AAH-BLG-1; RayBio-
tech Inc., Norcross, GA, USA) at the Genomics Core
Facility, Oslo University Hospital, as detailed previously
[5]. Briefly, proteins were biotinylated and added onto
glass slides pre-printed with 507 capture antibodies.
Bound proteins (in duplicates) were detected with a
streptavidin-conjugated fluorescent dye, and the result-
ing array image spots were converted to numerical
values. The array data is available in the Gene Expres-
sion Omnibus repository (GEO Accession Number
GSE65622).
Following data processing as detailed in the supple-
mentary information within the deposited data, the data
was transformed to natural logarithms and Significance
Analysis of Microarrays (SAM) software version 5.0 was
used to determine alterations in protein levels during
treatment by employing paired analysis and a false dis-
covery rate cut-off of 10 % [11]. SAM, originally devel-
oped for analysis of DNA microarrays, can also be
utilized for protein arrays. Herein, changes in protein
levels are identified by a set of t-tests, where each pro-
tein receives a score on the basis of its change relative to
the standard deviation of repeat measurements. This
software handles any missing data by imputation using
the K-nearest neighbor method [11]. Functional associ-
ation analysis of the resulting list of altered proteins was
performed by the Functional Coupling software version
3.0 [12] using a maximum of five nodes per expansion
step and a confidence threshold of 0.5.
ELISA analysis of LCN2 and MMP9
This was performed with the Quantikine® Human
Lipocalin-2/NGAL and MMP9 Immunoassays (R&D
Systems, Minneapolis, MN, USA) according to the man-
ufacturer’s manuals. For this analysis, serum samples
were diluted 1:20 and 1:200 for quantification of LCN2
and MMP9, respectively. All samples were analyzed in
duplicates.
Study endpoints
The clinical endpoints were treatment toxicities
(CTCAE scores) during neoadjuvant therapy, histologic
tumor response, and PFS. Follow-up data was censored
on August 8, 2013. Within the context of the study [8],
the resected tumor specimens were prepared in accord-
ance with the requirements of a validated protocol [13]
and histologically evaluated for treatment response ac-
cording to standard staging (ypTN; TNM version 5). In
this patient population of locally advanced tumors
(mainly T3–4 cases), ypT0–2 outcome was considered
as good response and correspondingly, ypT3–4 results
were regarded as poor tumor shrinkage. Moreover, re-
sponse in the resected specimen was graded within one
of five tumor regression grade (TRG) categories [14],
where TRG1 represents absence of residual tumor cells
(pathologic complete response), TRG2 corresponds to
the presence of sparsely remaining tumor cells scattered
in fibrosis or mucin, TRG3 is an intermediate score be-
tween TRG2 and TRG4, the latter defining residual
tumor that outgrows fibrosis or mucin, and TRG5 corre-
sponds to the lack of morphologic signs of response. Of
note, when responding to neoadjuvant treatment, LARC
frequently shows fragmentation into microscopic re-
sidual disease [15]. Consequently, it is rational to group
TRG2 together with TRG1 as good histologic regression
and correspondingly, the range of TRG3–5 scores as
poor response. In cases of ambiguity about the exact
histologic tumor response of the surgical specimen, the
meticulous procedure of targeted magnetic resonance-
guided histopathology [15] was applied.
Statistical analysis
Analyses were performed using IBM SPSS Statistics for
Windows version 23.0 or GraphPad Prism version 6.0 h.
Correlation between continuous data was determined by
Pearson product correlation analysis or one-way analysis
of ranks. Categorical data was compared by paired t-test.
Estimated 5-year PFS was calculated from the time of
study enrollment to the date of recurrent disease, death of
any cause, or end of follow-up (five years after the date of
surgery), whichever came first. Associations between se-
lected variables and PFS were modeled with univariate
Cox regression analysis. All tests were two-sided. A
p-value less than 0.05 was considered statistically sig-
nificant. Importantly, during array data processing,
some fluorescence intensity measurements were fil-
tered out, and that explains the differences between
the total number of patients with available array data
and the number of measurements for a particular
protein (Additional file 1: Table S1).
Results
Circulating proteins during the course of neoadjuvant
treatment
Using the antibody array, approximately 500 proteins were
measured in serial serum samples collected from the study
patients at baseline, post-NACT, post-CRT, and at evalu-
ation of the neoadjuvant treatment. Significant changes in
protein levels (fold-change relative to baseline) were ob-
served during the treatment course, but only for six pro-
teins (ADIPOQ, ANG, IL6ST, LCN2, MMP9, and
TNFRSF11B; identities given by the gene names) persist-
ently at every sampling point and considerably higher
numbers (38–46 proteins) at the post-CRT and evaluation
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sampling points (Table 1). Functional coupling analysis re-
vealed a high degree of interaction between some of the
altered proteins, and additionally, it predicted interactions
with proteins that were not present in the query list
(Fig. 2). One example, as can be seen from comparison of
Table 1 and Fig. 2, was thrombospondin-1 (THBS1),
which was not present in the list of proteins whose serum
levels were altered by NACT but was predicted as a func-
tional interaction partner of MMP9, one of the few
proteins with significant change at this early stage of treat-
ment. At CRT completion, however, the thrombospondin-
1 levels were also significantly altered from baseline. This
may indicate that the induction NACT initiated a bio-
logical response that was strongly enhanced by the
sequential CRT.
Validation of antibody array measurements
This was achieved by ELISA measurements of LCN2
and MMP9, being two of the six proteins that were
altered at every sampling point (Table 1). Another rea-
son for choosing these proteins for this purpose was that
LCN2 and MMP9 form a covalent complex [16], as
reflected in Fig. 2, and their regulatory role in tumor mi-
croenvironmental biology [17]. In serum samples from
24 randomly chosen patients, significant correlation be-
tween array measurements (in fluorescence intensities)
and serum protein levels (in ng/ml) was found for both
LCN2 and MMP9 at all sampling points with exception
of LCN2 post-CRT (Fig. 3).
Three of the four serum proteins that had significantly
increased array values from baseline at every subsequent
sampling point (ADIPOQ, ANG, and IL6ST; Table 1)
were not analyzed by alternative methods. The fourth of
the elevated proteins, the soluble tumor necrosis factor
decoy receptor TNFRSF11B, was thoroughly investigated
in a separate study which was recently reported [18]. In
neither case, altered array values were associated with
long-term patient outcome (Additional file 1: Table S2).
Table 1 Significantly altered serum proteins in study patients
Post-NACT Post-CRT Evaluation
ADIPOQ 1.15 ACVR1 1.10 IGFBP3 1.21 ADIPOQ 1.10 GRN 1.12
ANG 1.21 ADIPOQ 1.10 IGFBP7 1.12 ANG 1.11 IGF2 1.21
IGFBP2 1.15 ANG 1.21 IL1RAPL2 1.10 ANGPT2 1.16 IGFBP7 1.15
IL6ST 1.12 BMPR1A 1.11 IL27 1.12 BDNF 1.11 IL1RAPL2 1.11
NCAM1 1.12 CCL1 1.11 IL6ST 1.17 BMPR1A 1.18 IL22 1.12
SAA1 1.15 CCL11 1.12 LBP 1.16 CCL11 1.14 IL6ST 1.12
TNFRSF11B 1.34 CCL22 1.13 LEPR 1.11 CCR6 1.14 LIFR 1.12
CCR6 1.10 PLAU 1.12 CD14 1.13 MMP2 1.10
CD14 1.14 RARRES2 1.12 CSF1 1.19 NGFB 1.12
CSF1 1.22 RELT 1.11 CTF1 1.12 NTF4 1.13
EGFR 1.11 SAA1 1.27 CXCR1 1.19 RARRES2 1.23
ERBB2 1.20 SIGLEC5 1.14 CXCR5 1.11 SIGLEC9 1.12
FLT3LG 1.11 SIGLEC9 1.13 CXCR6 1.12 SLC2A2 1.19
GCG 1.13 SLC2A2 1.13 ERBB2 1.11 THBS4 1.12
GRN 1.16 TGFBR1 1.11 ERBB4 1.11 TNFRSF11B 1.16
IGF2 1.18 THBS4 1.10 FLT3LG 1.12
IGFBP2 1.15 TNFRSF11B 1.65
LCN2 0.65 CHRDL2 0.88 PDGFA 0.86 CHRDL2 0.86 PDGFA 0.88
LTBP1 0.87 CXCL2 0.88 PDGFB 0.89 FGF13 0.84 S100A12 0.84
MMP9 0.63 FGF13 0.83 PF4 0.85 LCN2 0.84 TMEFF2 0.89
LCN2 0.73 PPBP 0.83 MMP9 0.74
LTBP1 0.80 S100A12 0.85
MMP9 0.68 THBS1 0.84
Using the Significance Analysis of Microarrays software, serum protein levels (entered as antibody array fluorescence intensities transformed to natural logarithms)
that were significantly altered from baseline following induction neoadjuvant chemotherapy (post-NACT) and sequential chemoradiotherapy (post-CRT) and at
evaluation of the neoadjuvant treatment were determined. The fold-change increase or decrease from baseline is indicated to the right of each protein. False
discovery rate was less that 10 % for all proteins. Proteins are listed by their gene names. Proteins with serum levels that were significantly different from baseline
at every other sampling point are italicized. The protein highlighted in bold is also discussed in the current report. The crude table has been shown in a previous
report [18]
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Fig. 2 (See legend on next page.)
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Circulating LCN2 and MMP9 during neoadjuvant
treatment
Figure 4 illustrates serum levels of LCN2 and MMP9 as
determined by the antibody array. For both proteins, the
group values at all of the sampling points were signifi-
cantly lower than at baseline, with [median (range)
values given for LCN2 and MMP9, respectively] a post-
NACT fold-change decline to 0.44 (0.12–2.0) and 0.49
(0.14–3.3) followed by a gradual increase to 0.69 (0.11–
3.0) and 0.55 (0.07–5.0) post-CRT. At evaluation a few
weeks before surgery, LCN2 and MMP9 values had fur-
ther approached baseline with fold-changes of 0.86
(0.20–5.0) and 0.75 (0.12–3.9).
Circulating LCN2 and MMP9 and disease outcome
Since both the post-NACT and post-CRT sampling
points immediately followed completion of a defined
therapeutic modality, we investigated whether the indi-
vidual patient’s decline in serum levels might predict
response to the combined-modality therapy. No correla-
tions were seen for ypTN stage or TRG score
(Additional file 1: Table S3). When last censored, median
follow-up time for patients with the relevant paired
LCN2 and MMP9 measurements was 63 months (range
3–65). Three patients had experienced local recurrence
as the first event of disease relapse. In addition, 13 and
11 cases in the LCN2 and MMP9 groups, respectively,
had metastatic progression as the first event. Hence, PFS
was chosen as the relevant long-term endpoint.
On univariate Cox regression analysis (Table 2), histo-
logic treatment response was highly associated with clin-
ical outcome, underpinned by correlation of both ypT3–4
and ypN1–2 stages as well as TRG 3–5 scores with ad-
verse PFS. Moreover, the lower the post-NACT and post-
CRT MMP9 values (fold-change decline from baseline),
the more favorable PFS. With increasing MMP9 values
(i.e., less decline from baseline), the hazard ratio for a PFS
event was almost 3. For LCN2, the impact of post-NACT
and post-CRT changes on PFS just failed to reach signifi-
cance. Multivariate analysis was waived because of the low
number of PFS events. Differences in PFS between pa-
tients separated into groups based on the magnitude of
(See figure on previous page.)
Fig. 2 Functional coupling between proteins that changed in patients’ circulation during neoadjuvant therapy. Proteins are depicted by their
gene symbols. Yellow nodes: proteins whose serum levels significantly differed from baseline following induction neoadjuvant chemotherapy
(post-NACT) and sequential chemoradiotherapy (post-CRT) and at treatment evaluation. Non-yellow nodes: proteins not present in the query list
but predicted as interacting with the significantly altered proteins at the specific sampling point. Encircled nodes: proteins further analyzed
Fig. 3 Correlations between array fluorescence (FL) intensities and single-parameter immunoassay measurements. Values (transformed to natural
logarithms) of lipocalin-2 (LCN2) and matrix metalloproteinase-9 (MMP9) levels in serum samples obtained at baseline, following induction neoadjuvant
chemotherapy (post-NACT) and sequential chemoradiotherapy (post-CRT), and at treatment evaluation from 24 randomly chosen patients were compared
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the serum LCN2 and MMP9 changes are visualized in
Additional file 2: Figure S1.
Circulating LCN2 and MMP9 and treatment toxicities
Neither LCN2 nor MMP9 shows tumor-specific expres-
sion, and the release of these proteins into the circula-
tion from other tissues of origin might therefore change
as an adverse response to therapy. Because the present
study regimen caused intestinal toxicity [8], we investi-
gated the possibility that the extent of decline in serum
LCN2 and MMP9 levels might also, in susceptible indi-
viduals, predict treatment-induced enteropathy, clinically
presenting as diarrhea.
This analysis omitted patients reporting diarrhea at
baseline as a presenting symptom of their disease or
from whom definite maximum CTCAE score was not
available. The remaining cases (Additional file 1:
Table S1) were grouped according to maximum
CTCAE scores (from 0 to 3; no case of CTCAE grade
4 diarrhea was reported). As could be expected, the
scores recorded at CRT completion distinguished pa-
tients with respect to intestinal toxicity, consistent
with radiation-induced acute toxicity being cumula-
tive. While group 0 consisted of cases devoid of diar-
rhea (i.e., CTCAE grade 0) throughout the treatment
course, group 1, 2, and 3 patients reported CTCAE
grade 1, 2, and 3 post-CRT diarrhea, respectively.
With this categorization, using post-NACT and post-
CRT values of LCN2 and MMP9 (fold-change from
baseline) from cases that provided these particular
measurements (n = 38–49), no correlation was found
with this specific adverse treatment event (Additional
file 1: Table S4).
Moreover, because LCN2 is expressed in complex with
MMP9 in neutrophils specifically [9], we asked whether
the decline in serum levels might have reflected grave
neutropenia during NACT and CRT. However, only one
CTCAE grade 3 (and none grade 4) neutropenic event
was reported by the total population of 66 patients. Still,
the individual patient’s absolute neutrophil count at
completion of the systemic modality (NACT) showed
moderate correlation with both LCN2 and MMP9 values
(fold-change from baseline; LCN2: r = 0.35, p = 0.015;
MMP9: r = 0.44, p = 0.001). Other CTCAE grade 3–4
events recorded in the study population [8] were also
Fig. 4 Serum lipocalin-2 (LCN2) and matrix metalloproteinase-9 (MMP9) levels during neoadjuvant therapy. Array fluorescence intensities relative
to the individual patient’s baseline values following induction neoadjuvant chemotherapy (post-NACT; n = 50 for LCN2 and n = 61 for MMP9) and
sequential chemoradiotherapy (post-CRT; n = 48 for LCN2 and n = 57 for MMP9) and at treatment evaluation (n =50 for LCN2 and n =54 for
MMP9); lines, median group values; *p < 0.01; **p < 0.001; ***p < 0.0001
Table 2 Progression-free survival – univariate analysis
HR 95 % CI p-value
Age 1.0 0.95–1.9 0.12
TN stage T2–3
T4 1.9 1.0–3.9 0.06
N0
N1–2 0.97 0.38–2.5 0.95
Baseline CEA ≤ULN
>ULN 1.4 0.72–2.8 0.31
ypTN stage ypT0–2
ypT3–4 4.2 1.9–9.5 <0.001
ypN0
ypN1–2 3.7 1.8–7.5 <0.001
TRG score TRG1–2
TRG3–5 2.4 1.2–4.7 0.01
Post-NACT LCN2 2.2 1.0–4.8 0.05
MMP9 2.8 1.5–5.9 <0.01
Post-CRT LCN2 2.3 1.0–5.2 0.06
MMP9 2.9 1.1–3.4 0.03
Adjusted hazard ratio (HR) with 95 % confidence interval (CI); HR above 1:
higher probability of unfavorable progression-free survival for the higher
value(s) of the parameter. Age and altered serum values (array fluorescence
intensities) as fold-change from baseline of lipocalin-2 (LCN2) and matrix
metalloproteinase-9 (MMP9) after induction neoadjuvant chemotherapy
(post-NACT) and sequential chemoradiotherapy (post-CRT): entered as continuous
data from lowest to highest measurements. CEA carcinoembryonic antigen, ULN
upper limit of normal, TRG tumor regression grade
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infrequent and therefore deemed unsuitable for analysis
in the current study subpopulation.
Discussion
The essential idea of this study was to monitor circulat-
ing proteins in LARC patients receiving induction
NACT and sequential CRT using a multiplex antibody
array in an effort to quest readily accessible indicators of
treatment efficacy and toxicity to combined-modality
radiotherapy. Protein profiles from serial serum samples
collected at different stages of the treatment course were
related to PFS (patient outcome) and CTCAE scores
(patient tolerance), and the strategy was corroborated by
examining LCN2 and MMP9 specifically.
There are several advantages of using the antibody array
technology in the context of this study. In addition to pro-
teins being potentially targetable within a combined-
modality treatment protocol [7], their expression integrates
biological responses at transcription, post-translational
modification, and compartmentalization, including secre-
tion. Importantly, simultaneous analysis of a manifold of
proteins as compared to the investigation of single markers
gives a more complete picture of systemic patient responses
during the treatment course. However, high-throughput
technologies commonly come with certain limitations. De-
tection of only half a thousand out of an abundance of pro-
teins released into the serum compartment represents an
investigation bias. In addition, there are technical aspects
such as protein stability and non-specific binding, which
could result in low detection of some proteins or gener-
ation of false positives, respectively [19].
Since analytical pipelines for protein arrays are still at
their infancy, we adopted methods developed for gen-
omic data to place the findings into a biological context.
The array data revealed that only a few serum proteins
changed during the induction NACT but that the se-
quential CRT modality affected a substantial number. At
the time of treatment evaluation four weeks after CRT
completion, a major part of these protein alterations
were still present. Exploration of possible functional net-
works of the altered proteins indicated an emerging sys-
temic response elicited by the initial NACT which was
considerably amplified by the CRT, illustrated by the de-
tected immune factors, growth factors, and proteinases.
Importantly, the use of this technology for investigation
of circulating biomarkers within the context of a pro-
spective study represents a negligibly invasive approach
that may bring insights into the patients’ systemic re-
sponses with regard to both tumor and normal tissue ef-
fects to the various treatment modalities.
Since the antibody array at best is semi-quantitative,
any in-depth investigation of potential markers of treat-
ment response or adverse effects would require valid-
ation by a supplementary methodology. We chose two
proteins for single-parameter ELISA analysis – LCN2
and MMP9, and their serum levels in ng/ml showed sig-
nificant correlation with the array measurements in
fluorescence intensities. Levels of both factors declined
significantly following the induction NACT, then grad-
ually increased during the sequential CRT, and finally
reverted close to baseline at the evaluation sampling
point. MMP9 is involved in extracellular matrix remod-
eling [10] and LCN2, which is predominantly produced
by neutrophils, forms a covalent complex with MMP9
and protects it from auto-degradation [9, 16, 20, 21]. En-
hanced tissue expression as well as circulating levels of
LCN2 and MMP9, or their complex, have been observed
in several tumor entities [9, 22–25]. In a study of pri-
marily resected colorectal cancers, primary tumor
MMP9 expression was an independent predictor of
disease-free survival [26]. Baseline tumor biopsies in our
study, which were sampled from the endoluminal sur-
face of the deeply invasive tumors, would probably not
have enabled a reliable estimation of whole tumor
MMP9 expression for direct comparison with the pa-
tients’ circulating MMP9 levels. Nevertheless, baseline
serum levels of LCN2 and MMP9 (as determined by the
ELISA measurements) in 24 cases were similar to previ-
ously reported values in patients with colorectal cancer
[27–29] and considerably higher than those in healthy
subjects [22]. Distinct declines in serum MMP9 levels
following the course of treatment initiation and sequen-
tial CRT were associated with advantageous PFS. It is
tempting to speculate that NACT, as induction chemo-
therapy, and aided by the CRT, may specifically have tar-
geted tumor microenvironmental components with
MMP9-regulated inflammatory and metastatic proper-
ties [17] in good-prognosis patients.
Importantly, we could not exclude the possibility that
alterations in serum contents of LCN2 and MMP9
reflected deleterious normal tissue effects. With the par-
ticular study design, the pelvic CRT caused intestinal
toxicity [8]. Moreover, any associations between circulat-
ing LCN2 and MMP9 levels and neutrophil counts [9]
during chemotherapy should be considered. In other
words, both the normal bowel and neutrophils locally or
systemically might contribute to alterations in circulat-
ing levels of these proteins. However, there was no cor-
relation between the decline in serum levels of LCN2
and MMP9 and the diarrhea score. Essentially, the study
displayed low incidence of CTCAE grade 3–4 adverse ef-
fects, probably reflecting the precaution criteria in the
study protocol. In this, the neoadjuvant treatment sched-
ule was continuously adjusted according to toxicity by
reducing doses of or entirely discontinuing oxaliplatin,
capecitabine, or radiotherapy in that order of priority, in
accordance with the relative importance of the three
therapeutic components within the study regimen. These
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safety concerns may have precluded the quest for circu-
lating markers of treatment toxicity.
Of note, the number of study cases from whom serum
samples were available was small (from 66 at baseline to
55 before surgery), although a tentative sample size ana-
lysis using 5-year PFS rates as estimated in Additional
file 2: Figure S1 indicated that the numbers of post-
NACT LCN2 and MMP9 cases and post-CRT MMP9
cases were sufficient for the purpose. Nevertheless, the
study findings should ideally have been evaluated in an
independent patient cohort where cases had undergone
combined-modality radiotherapy with curative intent for
a pelvic malignancy along with the simultaneous pro-
spective serial sampling of serum (or plasma) through-
out the treatment course and where additionally, results
from prospective recording of adverse events and long-
term outcome data were available. Our attempts into
identifying such validation material have not been
successful.
Conclusions
To summarize, this report is based on a prospective
study of an intensified neoadjuvant therapy regimen in
LARC patients with median follow-up time of five years
after definitive surgery. The study population of mainly
T3–4 cases was treated with curative intent but had
metastatic progression as a main PFS event, and the re-
corded spectrum of CTCAE grade 0–3 diarrhea scores
reflected the range of individual adverse responses to the
therapy. As a conceptual approach to delineate possible
mechanisms involved in tumor and systemic responses
to the combined-modality radiotherapy, we employed a
high-density antibody array technology to monitor
changes in patients’ serum protein levels during the
treatment course. The experimental strategy was illus-
trated by further investigation of selected proteins, and
specifically, treatment-induced changes in circulating
MMP9 levels were associated with PFS but not treat-
ment toxicity. However, the current study had several
limitations specifically with regard to a rather low pa-
tient number, and further studies with larger populations
are required to validate the overall design as well as the
specific findings.
Essentially, in order to improve long-term outcome of
advanced cancer disease, increasingly complex contem-
porary therapies raise the requirement for biological in-
dicators of treatment efficacy and toxicity (i.e., patient
outcome and tolerance). In this context, the use of
multiplex immunoassay technology to monitor circulat-
ing proteins in patients undergoing a combined-
modality treatment program may represent a promising
path to treatment-related biomarker discovery. Analysis
of several markers simultaneously, as opposed to single
candidates, may enlighten the complex biological
responses that are elicited, and the detection of alter-
ations in protein levels at different stages of the treat-
ment course may help in dissecting the contribution of
the single modalities to the overall treatment response
or adverse effects.
Additional files
Additional file 1: Table S1. Numbers of serum samples from study
patients. The initial population of 66 study patients had serum sampled
at baseline, following induction neoadjuvant chemotherapy (post-NACT)
and sequential chemoradiotherapy (post-CRT), and at evaluation of the
neoadjuvant treatment. Applying Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0 and omitting cases reporting CTCAE
grade >0 diarrhea at baseline or from whom definite maximum CTCAE
score was not available, the initial number of 53 study patients remained
for the analysis of treatment toxicity (maximum diarrhea CTCAE score)
during the neoadjuvant treatment course. Missing values as a result of
processing of the antibody array data from serum samples led to
reduction in the number of cases with lipocalin-2 (LCN2) and matrix
metalloproteinase-9 (MMP9) measurements and subsequently, the
number of cases with matched values for fold-change from baseline
ratios available for down-stream analyses. Table S2. Association between
altered serum values (array fluorescence intensities as fold-change from
baseline) of the four listed proteins (identities given by the gene names)
at completion of induction neoadjuvant chemotherapy (post-NACT) and
sequential chemoradiotherapy (post-CRT), entered as continuous data
from lowest to highest measurements, and PFS was modeled by Cox
regression analysis and given as adjusted hazard ratio (HR) with 95%
confidence interval (CI); HR above 1: higher probability of unfavorable
PFS for the higher value(s) of the parameter. In neither case, altered array
values at completion of NACT or CRT were associated with PFS. Table
S3. Study patients’ characteristics. The initial population of 66 study
patients had serum sampled at baseline, following induction neoadjuvant
chemotherapy (post-NACT) and sequential chemoradiotherapy (post-
CRT), and at evaluation of the neoadjuvant treatment. One patient had
disease progression in the pelvic cavity during the neoadjuvant treatment
and therefore proceeded to palliative surgery. As a consequence, histologic
tumor response data (ypTN stage and tumor regression grade (TRG) scoring)
were missing. The serum samples were analyzed with an antibody array.
Array data processing led to reduction in the number of cases with
lipocalin-2 (LCN2) and matrix metalloproteinase-9 (MMP9) measurements
and subsequently, the number of cases with matched values for fold-
change from baseline ratios – given here – that were available for down-
stream analyses. Distribution of parameters was analyzed using Pearson
product correlation for continuous data and paired t-test for categorical
variables. Within the total study population as well as all of the LCN2 and
MMP9 groups of study cases, patients’ characteristics were equally
distributed. Table S4. Treatment-induced enteropathy in study patients.
Using one-way analysis of ranks, altered serum values (array fluorescence
intensities as fold-change from baseline) of lipocalin-2 (LCN2) and
matrix metalloproteinase-9 (MMP9) following induction neoadjuvant
chemotherapy (post-NACT) and sequential chemoradiotherapy (post-
CRT) were compared for patients categorized into four groups of
maximum diarrhea scores, as assessed by Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0, during the neoadjuvant treatment
course. Categories are Group 0: CTCAE grade 0 diarrhea; Group 1: CTCAE
grade 1 diarrhea; Group 2: CTCAE grade 2 diarrhea; Group 3: CTCAE grade 3
diarrhea. (DOC 99 kb)
Additional file 2: Figure S1. Alterations in serum levels of lipocalin-2
(LCN2; left panel) and matrix metalloproteinase-9 (MMP9; right panel) –
progression-free survival (PFS). Patients were categorized into groups
according to the magnitude of decline in serum values (array fluorescence
intensities as fold-change from baseline) at completion of induction
neoadjuvant chemotherapy which resulted in a value either below
(solid line) or above (dashed line) a calculated optimum threshold
(by receiver-operating characteristic analysis) for favorable PFS. Crude
differences in PFS were assessed by the log-rank test and visualized
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by the Kaplan-Meier method. Patients with fold-change values below
threshold (i.e., more decline from baseline) during the chemotherapy
had significantly better 5-year PFS than those with fold-change values
above threshold (i.e., less decline from baseline); for LCN2: 76% versus
38% (p = 0.004, n = 50, threshold of 0.8); for MMP9: 76% versus 20%
(p = 0.0002, n = 61, threshold of 1.0). The corresponding identification of
optimum threshold values for LCN2 and MMP9 alterations at completion of
the sequential chemoradiotherapy was not possible with the actual data
sets. (DOC 1827 kb)
Abbreviations
CRT, chemoradiotherapy; CTCAE, Common Terminology Criteria for Adverse
Events; ELISA, enzyme-linked immunosorbent assay; LARC, locally advanced
rectal cancer; LCN2, lipocalin-2; MMP9, matrix metalloproteinase-9; NACT,
neoadjuvant chemotherapy; PFS, progression-free survival; SAM, Significance
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